Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Hepatitis Testing/Diagnosis Market
The Hepatitis Testing/Diagnosis Market addresses a critical segment within infectious disease diagnostics, focusing on tools for detecting hepatitis viruses (Hepatitis B, C, D, A, and others) to enable early intervention and reduce transmission. The market’s growth is driven by high global prevalence of chronic hepatitis infections, technological advancements in diagnostic tools, and increasing public health initiatives aimed at elimination. Key stakeholders include hospitals, diagnostic laboratories, blood banks, and public health programs, all of which rely on accurate and accessible testing solutions to manage and mitigate the burden of hepatitis.
Market size
Growth trajectory through 2035
Hepatitis Testing/Diagnosis Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 AI Integration in Diagnostics
- Companies are increasingly incorporating AI and machine learning into hepatitis diagnostic tools to improve accuracy, reduce turnaround times, and enable predictive analytics.
-
Development 02 Home Testing Expansion
- The launch of FDA-cleared and CE-marked home testing kits for hepatitis B and C has expanded access to testing, particularly in underserved populations.
-
Development 03 Government Initiatives
- National hepatitis elimination programs in countries like Australia, Brazil, and the UK have led to increased funding for testing and treatment, driving market growth.
-
Development 04 Technological Advancements
- Innovations such as CRISPR-based diagnostics and next-generation sequencing are being explored for their potential to revolutionize hepatitis testing.
Emerging opportunities added
- AI-Powered Diagnostics Artificial intelligence is transforming hepatitis diagnostics by accelerating drug discovery, improving patient response predictions, and enhancing early detection through advanced imaging analysis.
- Expansion of Home Testing The rising demand for at-home testing solutions presents opportunities for manufacturers to develop cost-effective, user-friendly kits that increase testing accessibility.
- Public-Private Partnerships Collaborations between governments, NGOs, and private sector stakeholders can expand testing programs, particularly in high-burden regions.
- Technological Convergence Integration of molecular diagnostics with digital health platforms can streamline data management and improve patient outcomes through real-time monitoring.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $4.02 Bn
- CAGR
- 5.20%
- Expansion
- 1.7×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- throughput testing and specialized assays
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory Hurdles
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
AI Integration in Diagnostics: Companies are increasingly incorporating AI and machine learning into hepatitis diagnostic tools to improve accuracy, reduce turnaround times, and enable predictive analytics
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 100-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Hepatitis Testing/Diagnosis Market today ($4.02 Bn base), and how fast will it grow at 5.2% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Growing Awareness and Education) and top restraints (led by Regulatory Hurdles), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Growing Awareness and Education Public health campaigns and educational initiatives are increasing awareness of hepatitis risks and the importance of early detection, driving demand for diagnostic solutions.
- Technological Innovations Advances such as point-of-care testing, rapid diagnostic tests, and molecular diagnostics are improving the accuracy, speed, and accessibility of hepatitis testing, enabling timely intervention.
- Government Initiatives and Funding National strategies to eliminate hepatitis as a public health threat, including increased funding for testing and treatment programs, are creating a favorable environment for market growth.
- Rising Prevalence of Hepatitis Infections The increasing incidence of hepatitis B and C infections globally is prompting healthcare systems to enhance testing capabilities, expanding the market.
- Trend Towards Home Testing Solutions The growing preference for convenience and privacy is driving the development and distribution of user-friendly home testing kits, further increasing testing rates.
Restraints
Holding it back
- Regulatory Hurdles Approval timelines for new diagnostic tools can extend by 6–12 months post-2025, delaying market entry for innovative solutions.
- Supply Chain Challenges Component shortages, particularly for molecular diagnostics and rapid test kits, persisted through H1 2025, impacting production and distribution.
- Cost Constraints in Low-Resource Settings High costs of advanced diagnostic technologies limit adoption in low- and middle-income countries, where hepatitis burden is highest.
- Limited Awareness in Underserved Populations Persistent gaps in education and access to healthcare in rural and marginalized communities hinder widespread testing uptake.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Growing Awareness and Education | +2.3% | Global | 2025–2035 |
| Technological Innovations | +1.5% | Global | 2025–2035 |
| Government Initiatives and Funding | +1.1% | Global | 2025–2035 |
| Rising Prevalence of Hepatitis Infections | +0.8% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory Hurdles | −0.9% | Global | 2025–2029 |
| Supply Chain Challenges | −0.6% | Global | 2025–2029 |
| Cost Constraints in Low-Resource Settings | −0.5% | Global | 2025–2029 |
The hepatitis testing/diagnosis market is segmented by disease type, technology, end-user, and region.
Revenue share by type · 2025 base year
% OF $4.02 BN HEPATITIS TESTING/DIAGNOSIS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $4.02 Bn Hepatitis Testing/Diagnosis Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By technology
-
of
-
care solutions enabling quick results in resource
-
limited settings
-
sensitivity detection
By end-user industry
-
throughput testing and specialized assays
-
transmitted infections
-
chart
-
template="vbar_gradient" data
-
palette="muted_green">
-
color="#065f46"/>
-
color="#6ee7b7"/>
-
size="15" fill="#0f172a" text
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $4.02 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~43.7% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The hepatitis testing/diagnosis market is highly competitive, with key players focusing on technological innovation, strategic partnerships, and geographic expansion to maintain market share.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
What is the worth of the global hepatitis testing/diagnosis market?
The hepatitis testing/diagnosis market size had crossed USD 2.66 Billion in 2020 and will observe a CAGR of 5% up to 2029 driven by the high burden of hepatitis, increased blood transfusions and donations, the benefits of POC devices and kits, and hepatitis awareness programs -
What is the size of the North America hepatitis testing/diagnosis industry?
North America held more than 35% of the hepatitis testing/diagnosis market revenue share in 2020 and will witness expansion with the rising prevalence of hepatitis, as well as increased research and clinical trials for hepatitis testing -
What are the upcoming trends in the hepatitis testing/diagnosis market, globally?
The upcoming trends in the hepatitis testing/diagnosis market are rising consumer awareness. -
What is the CAGR of the hepatitis testing/diagnosis market?
The global hepatitis testing/diagnosis market registered a CAGR of 5 % from 2022 to 2029. The hepatitis B segment was the highest revenue contributor to the market. -
Which are the top companies to hold the market share in the hepatitis testing/diagnosis market?
Key players profiled in the report include F. Hoffmann-La Roche Ltd, Abbott, Bio-Rad Laboratories Inc., Siemens, DiaSorin, QIAGEN, Danaher, bioMérieux SA, Grifols S.A., Ortho Clinical Diagnostics, FUJIREBIO Inc. -
What is the leading application of the hepatitis testing/diagnosis market?
It is used to test/ diagnose the hepatitis virus. -
Which is the largest regional market for the hepatitis testing/diagnosis market?
North America is the largest regional market for hepatitis testing/diagnosis market
The Hepatitis Testing/Diagnosis Market is projected to reach $6.67 Bn by 2035, up from $4.02 Bn in 2025 — a 5.20% CAGR equating to roughly 1.7× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.